Edwards Lifesciences Corporation $EW Shares Sold by Forsta AP Fonden

Forsta AP Fonden trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 121,300 shares of the medical research company’s stock after selling 900 shares during the quarter. Forsta AP Fonden’s holdings in Edwards Lifesciences were worth $9,487,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Rosenberg Matthew Hamilton acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $28,000. Quantbot Technologies LP acquired a new position in Edwards Lifesciences during the first quarter worth $26,000. NewSquare Capital LLC raised its position in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares in the last quarter. SouthState Corp acquired a new stake in Edwards Lifesciences in the first quarter valued at $27,000. Finally, Costello Asset Management INC acquired a new stake in Edwards Lifesciences in the first quarter valued at $29,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Citigroup upped their target price on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Deutsche Bank Aktiengesellschaft boosted their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Finally, National Bankshares set a $92.00 target price on Edwards Lifesciences in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Stock Up 0.7%

EW opened at $86.17 on Friday. The firm has a market cap of $50.00 billion, a P/E ratio of 12.40, a PEG ratio of 3.97 and a beta of 1.03. The business’s fifty day simple moving average is $78.09 and its 200 day simple moving average is $77.65. Edwards Lifesciences Corporation has a 52 week low of $65.31 and a 52 week high of $87.21. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 22,970 shares of company stock valued at $1,862,878 in the last quarter. 0.34% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.